What is MS Bioworks?
MS Bioworks operates as a specialized provider of protein mass spectrometry and proteomics services, serving as a vital partner for pharmaceutical and academic institutions. With a proven track record of processing over 70,000 samples and completing more than 12,000 projects, the firm has established a reputation for technical excellence in quantitative proteomics and protein complex mapping. Their state-of-the-art laboratory environment is designed to handle high-resolution spatial proteomics and post-translational modification analysis, positioning the company as a cornerstone of modern biological research workflows. Beyond its technical capabilities, the organization integrates environmental stewardship into its business model, reflecting a commitment to sustainable scientific advancement.
How much funding has MS Bioworks raised?
MS Bioworks has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in MS Bioworks
PPP
Public-Private Partnership
What's next for MS Bioworks?
With this recent strategic financing, MS Bioworks is well-positioned to expand its laboratory throughput and enhance its suite of analytical offerings. The company is expected to focus on deepening its market penetration in the life sciences sector, potentially investing in advanced instrumentation to maintain its competitive edge in high-resolution proteomics. As the demand for precise biological data grows, the firm's ability to scale its operations while maintaining rigorous quality standards will be a key driver of its long-term growth trajectory. Future initiatives will likely center on optimizing service delivery and broadening its reach within the global research community.
See full MS Bioworks company page
